EE500 Cost-Utility Analysis of Dupilumab Versus Omalizumab in the Treatment of Severe Asthma in China
Jul 1, 2025, 00:00
10.1016/j.jval.2025.04.2096
https://www.valueinhealthjournal.com/article/S1098-3015(25)02225-9/fulltext
Title :
EE500 Cost-Utility Analysis of Dupilumab Versus Omalizumab in the Treatment of Severe Asthma in China
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(25)02225-9&doi=10.1016/j.jval.2025.04.2096
First page :
Section Title :
Open access? :
No
Section Order :
10267